Conventional and atypical antipsychotics and the evolving standard of care

Psychiatric Services

Volumn 51, Issue 12, 2000, Pages 1528-1535

  Mossman, D ^a   Lehrer, D S ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; BUDGET; DRUG COST; MALPRACTICE; MENTAL HEALTH CARE; PATIENT EDUCATION; PATIENT RIGHT; PRESCRIPTION; PSYCHIATRIST; PSYCHOSIS; UNITED STATES;

ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL HEALTH SERVICES; PATIENT ADVOCACY; PHYSICIAN-PATIENT RELATIONS; PSYCHOTIC DISORDERS;

EID: 0033671740     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.51.12.1528     Document Type: Article

References (100)

1. Antipsychotic drag doses and neuroleptic/dopamine receptors
2. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
3. Conventional antipsychotic medications for schizophrenia
4. The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
5. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
6. Pharmacokinetics and pharmacodynamics of clozapine
7. American Psychiatric Association practice guideline for the treatment of patients with Schizophrenia
8. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia
9. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
10. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
11. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
12. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis
13. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis
14. Texas Medication Algorithm Project: Definitions, rationale, and methods to develop medication algorithms
15. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms
16. The Texas Medication Algorithm Project: Development and implementation of the schizophrenia algorithm
17. Medication algorithms for bipolar disorder
18. Tardive dyskinesia: Tremors in law and medicine
19. Consultant for the pharmacotherapy of schizophrenia
20. Quality of life and new antipsychotics in schizophrenia: Are patients better off?
21. Pharmacoeconomic studies of atypical antipsychotics: Review and perspective
22. Paying the piper for pharmacoeconomic studies
23. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: Implications for schizophrenia treatment
24. Patients with schizophrenia at risk for excessive antipsychotic dosing
25. Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose
26. A decision analysis approach to neuroleptic dosing: Insights from a mathematical model
27. 2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
28. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
29. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
30. Novel antipsychotics: Comparison of weight gain liabilities
31. Novel antipsychotics and new onset diabetes
32. Weight gain associated with antipsychotic drugs
33. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
34. Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia
35. Hospitalization rates among clozapinetreated patients: A prospecive cost-benefit analysis
36. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
37. Cost-effectiveness of clozapine: A UK clinic-based study
38. Initiating clozapine treatment in the outpatient clinic: Service utilization and cost trends
39. Impact of newer antipsychotics on outcomes in schizophrenia
40. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia
41. Economic outcomes of antipsychotic agents in a Medicaid population: Traditional agents vs risperidone
42. Impact of risperidone on the use of mental health care resources
43. Treatment costs and patient outcomes with use of risperidone in a public mental health setting
44. A naturalistic study of clinical use of risperidone
45. Effectiveness of antipsychotic therapy in a naturalistic setting: A comparison between risperidone, perphenazine, and haloperidol
46. Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France
47. Risperidone versus haloperidol: II. Cost-effectiveness
48. Cost-effectiveness of clozapine in patients with high and low levels of hospital use
49. Outcome in schizophrenia: Beyond symptom reduction
50. Risperidone: Clinical outcome predictors and cost-effectiveness in a naturalistic setting
51. Confronting policies that restrict medication choices
52. Clozapine's cost-benefit balance questioned
53. Malpractice implications of prescribing antipsychotic medications
54. Letter to Sally K Richardson, Director of Medicaid Operations at the Health Care Financing Administration
55. Atypicals aren't being prescribed to the elderly
56. Side effects of autipsychotic medications: Physicians' choice of medication and patient compliance
57. Violence and severe mental illness: The effects of substance abuse and nonadherence to medication
58. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome
59. Assessing the effects of atypical antipsychotics on negative symptoms
60. Differential effects of olanzapine for deficit and nondeficit negative symptoms in schizophrenia
61. Novel antipsychotic agents and their implications for forensic psychiatry
62. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia
63. The psychiatric patient's right to effective treatment: Implications of Osheroff v Chestnut Lodge